What Researchers Did
The authors wrote a review of pulmonary mucormycosis, a serious fungal lung infection, covering who gets it, why it is hard to treat, and which treatments offer the best chance of survival.
What They Found
This review describes mucormycosis as a life-threatening opportunistic fungal infection that affects people with weakened immune defences, including those with severe neutropenia, those taking corticosteroids or other immunosuppressive medicines, those with poorly controlled diabetes, and those with iron overload. It has recently appeared as a breakthrough sinopulmonary infection in blood cancer patients and transplant recipients who were taking antifungal prophylaxis that does not work against Mucorales. Unlike pulmonary aspergillosis, the outlook for pulmonary mucormycosis has not improved much over the last decade, mainly because early diagnosis is difficult and current antifungal drugs have limited activity against Mucorales. The authors state that prompt lipid amphotericin B-based antifungal therapy, reversal of underlying host factors, and an aggressive surgical approach offer the best chances for survival.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a narrative review rather than a trial, so the abstract reports no new patient data, and it does not describe how the literature was selected or compare treatments directly.